A Multiple Ascending Dose, Phase 1, Double-Blind, Study to Investigate the Safety and Pharmacokinetics of NTRX-07 in Healthy Volunteers and Patients With Early Alzheimer's Disease (AD), With an Exploratory Fed-Fasted Assessment
NeuroTherapia, Inc. is advancing NTRX-07, an investigational orally administered CB2 agonist, through a Phase 1 clinical trial targeting early Alzheimer's Disease (AD) and mild cognitive impairment (MCI). The Alzheimer's therapeutics market is projected to grow significantly, driven by the increasing prevalence of the disease and the demand for effective treatments. NTRX-07's unique mechanism of action may position it favorably against existing therapies, particularly in a landscape where disease-modifying treatments are scarce. The completion of this trial could enhance NeuroTherapia's portfolio and attract potential partnerships or acquisitions, especially if safety and pharmacokinetic profiles are favorable.
Indication: Alzheimer Disease
Modality: small molecule
Target: CB2 receptor agonist
Sponsor: NeuroTherapia, Inc.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 07, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CB2 receptor agonist
View original source fields
Condition raw: Alzheimer Disease
Condition normalized: Alzheimer Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: CB2 receptor agonist
Target normalized: CB2 receptor agonist